23 November 2021

Cancer stem cell markers

Targeting cancer stem cells is a therapeutic strategy that holds hope for the improvement of patients’ survival.


Cancer stem cells (CSCs) are a small number of cells, usually 1% to 3% of all cells in a tumor, that drive the tumor’s initiation, growth and metastasis, and may cause relapse. Due to their importance, several biomarkers that characterize CSCs have been identified, allowing diagnostic, therapeutic, and prognostic predictions. Thus, selectively targeting CSCs with various agents holds hope for improvement of cancer patients’ survival and is a promising therapeutic strategy against cancer. This white paper provides an overview of the most prominent CSC markers, focusing on solid cancers (lung, stomach, liver, breast, and colorectal cancers) and hematological cancers (acute and chronic myeloid leukemias).

Selection of cancer stem cell markers

Anti-ALDH1A1 (HPA002123)
Anti-BMI1 (HPA030471)
Anti-CD24 (HPA045879)
Anti-CD44 (HPA005785)
Anti-CTNNBL1 (HPA027907)
Anti-FOXO3 (HPA063104)
Anti-IL2RA (HPA054622)
Anti-NANOG (AMAb91393)
Anti-NES (AMAb90556)
Anti-THY1 (AMAb90844)
More cancer stem cell markers from Atlas Antibodies can be found in our webshop.

Related articles

Newsletter for researchers

We gladly support you by keeping you updated on our latest products and the developments around our services.